Preparation and evaluation of homologous IgG on canine parvovirus

Document Type : Full paper (Original article)

Authors

1 Department of Animal Virology, Research and Diagnosis, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Organization (AREEO), Karaj, Iran

2 Department of Sera Purification, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Organization (AREEO), Karaj, Iran

3 Department of Internal Medicine, Veterinary Faculty, University of Tehran, Tehran, Iran

4 Dog Training Center of Anti-Narcotic Police (SEPCA), Karaj, Iran

5 Department of Clinical Trial, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Organization (AREEO), Karaj, Iran

10.22099/ijvr.2025.52828.7901

Abstract

Background: Canine parvovirus, an important and highly pathogenic agent for puppies, is distributed worldwide. Despite the various vaccines being available, it is not easily prevented. Immunoglobulin therapy has been attempted as a supportive approach to cure affected puppies. Aims: In order to achieve a homologous immunoglobulin G (IgG) for the treatment of the fatal parvovirus, the purification of anti-parvovirus IgG from immunized dogs was assayed. Methods: IgG purification was conducted on the obtained immune sera using two-stage dialysis, in which various concentrations of ammonium sulfate with several incubations and centrifugations were applied in multiple steps. Results: Using SDS-PAGE electrophoresis, the correct band sizes of the purified IgGs were observed and its concentration was assessed to be >22 mg/ml. Also, using quantitative ELISA, the specific anti-parvovirus IgG titer of the purified dog IgG was calculated to be considerably above the protective threshold titer. To do so, 13 parvoviral diarrheic puppies were randomly categorized into 3 treatment groups for 5 consecutive days. Administration of 4, 8 and 16 mg/kg bw/d of purified IgG to these puppies significantly improved all clinical symptoms including diarrhea, dehydration, appetite, vomiting and white blood cell (WBC) in all affected puppies in dose-dependent manner, comparing with those in the placebo-controlled group (n=8) that experienced 2 deaths, too. Conclusion: This homologous anti-parvovirus IgG, which was purified through a novel, simple and inexpensive technology is expected to pass further clinical trials. Also, this IgG has the potential as a commercial product to reduce the burden of parvovirus infection in puppies.

Keywords

Main Subjects

References

Acciacca, RA; Sullivan, LA; Webb, TL; Johnson, V and Dow, SW (2020). Clinical evaluation of hyperimmune plasma for treatment of dogs with naturally occurring parvoviral enteritis. J. Vet. Emerg. Crit. Care (San Antonio), 30: 525-533.
Altman, KD; Kelman, M and Ward, MP (2017). Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure? Vet. Microbiol., 210: 8-16.
Ballow, MC (2019). 84 - Immunoglobulin therapy: Replacement and immunomodulation. In: Rich, RR; Fleisher, TA; Shearer, WT; Schroeder, HW; Frew, AJ and Weyand, CM (Eds.), Clinical immunology (5th Edn.), London, Elsevier. PP: 1143-1153.
Barahona Afonso, AF and João, CM (2016). The production processes and biological effects of intravenous immunoglobulin. Biomolecules. 6: 15.
Bragg, RF; Duffy, AL; DeCecco, FA; Chung, DK; Green, MT; Veir, JK and Dow, SW (2012). Clinical evaluation of a single dose of immune plasma for treatment of canine parvovirus infection. J. Am. Vet. Med. Assoc., 240: 700-704.
Casadevall, A; Dadachova, E and Pirofski, LA (2004). Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol., 2: 695-703.
Ferrara, G; Zumla, A and Maeurer, M (2012). Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections. Am. J. Med., 125: 1031-1038.
Ge, S; Xu, L; Li, B; Zhong, F; Liu, X and Zhang, X (2020). Canine parvovirus is diagnosed and neutralized by chicken IgY-scFv generated against the virus capsid protein. Vet. Res., 51: 110.
Ge, S; Zhang, X; Zhong, F; Liu, X and Zhang, X (2021). Generation and evaluation of IgY-scFv based mimetics against canine parvovirus. Vet. Res., 52: 70.
Gerlach, M; Proksch, AL; Unterer, S; Speck, S; Truyen, U and Hartmann, K (2017). Efficacy of feline anti-parvovirus antibodies in the treatment of canine parvovirus infection. J. Small Anim. Pract., 58: 408-415.
Ishibashi, K; Maede, Y; Ohsugi, T; Onuma, M and Mikami, T (1983). Serotherapy for dogs infected with canine parvovirus. Jpn. J. Vet. Sci., 45: 59-66.
Kotb, AM and Abdel Aziz, WR (2015). Efficacy of canine parvovirus hyperimmune serum prepared in horses for treatment of canine parvo and feline panleucopenia infections. Benha Vet. Med. J., 28: 34-39.
Larson, L; Miller, L; Margiasso, M; Piontkowski, M; Tremblay, D; Dykstra, S; Miller, J; Slagter, BJ; Champ, D; Keil, D; Patel, M and Wasmoen, T (2024). Early administration of canine parvovirus monoclonal antibody prevented mortality after experimental challenge. J. Am. Vet. Med. Assoc., 262: 506-512.
Liu, J; Zhang, Z; Bai, A; Sha, Y; Ma, L; Qin, S; Chen, F; Qin, S and Wu, J (2021). Prophylactic efficacy of equine immunoglobulin F(ab') (2) fragments against feline parvovirus. Appl. Biochem. Biotechnol., 193: 3151-3162.
Mazzaferro, EM (2020). Update on canine parvoviral enteritis. Vet. Clin. North Am. Small Anim. Pract., 50: 1307-1325.
Meunier, PC; Cooper, BJ; Appel, MJ and Slauson, DO (1985). Pathogenesis of canine parvovirus enteritis: the importance of viremia. Vet. Pathol., 22: 60-71.
Mithilesh, S; Rajendran, M; Ujjwal Kumar, D; Vishal, C; Babul Rudra, P; Saravanan, R and Darshini, M (2022). Canine parvovirus-2: An emerging threat to young pets, In: Fonseca-Alves, CE and Payan-Crreira, R (Eds.), Recent advances in canine medicine. (1st Edn.), IntechOpen, Rijeka. PP: 1-27.
Pantaleo, G; Correia, B; Fenwick, C; Joo, VS and Perez, L (2022). Antibodies to combat viral infections: development strategies and progress. Nat. Rev. Drug Discov., 21: 676-696.
Parrish, CR and Sykes, JE (2023). Canine parvovirus infections and other viral enteritides. In: Skyes, JE (Ed.), Green’s infectious diseases of the dog and cat. (5th Edn.), Missouri, USA, Elsevier. PP: 1123-1157.
Pati, I; Cruciani, M; Candura, F; Massari, MS; Piccinini, V; Masiello, F; Profili, S; De Fulvio, L; Pupella, S and De Angelis, V (2023). Hyperimmune globulins for the management of infectious diseases. Viruses. 15: 1543.
Perez, EE; Orange, JS; Bonilla, F; Chinen, J; Chinn, IK; Dorsey, M; El-Gamal, Y; Harville, TO; Hossny, E; Mazer, B; Nelson, R; Secord, E; Jordan, SC; Stiehm, ER; Vo, AA and Ballow, M (2017). Update on the use of immunoglobulin in human disease: A review of evidence. J. Allergy Clin. Immunol., 139: S1-S46.
Perricone, C; Triggianese, P; Bursi, R; Cafaro, G; Bartoloni, E; Chimenti, MS; Gerli, R and Perricone, R (2021). Intravenous immunoglobulins at the crossroad of autoimmunity and viral infections. Microorganisms. 9: 121.
Rizzi, MA (2022). Hematology of dog. In: Brooks, MB; Harr, KE; Wardrop, KJ and Weiss, DJ (Eds.), Schalm’s veterinary hematology. (7th Edn.), Wiley, Chichester, UK. PP: 971-982.
Rockman, S; Lowther, S; Camuglia, S; Vandenberg, K; Taylor, S; Fabri, L; Miescher, S; Pearse, M; Middleton, D; Kent, SJ and Maher, D (2017). Intravenous immunoglobulin protects against severe pandemic influenza infection. EbioMedicine. 19: 119-127.
Salazar, G; Zhang, N; Fu, TM and An, Z (2017). Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines. 2: 19.
Schwab, I and Nimmerjahn, F (2013). Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol., 13: 176-189.
Shao, Z; Feng, Y; Zhong, L; Xie, Q; Lei, M; Liu, Z; Wang, C; Ji, J; Liu, H; Gu, Z; Hu, Z; Su, L; Wu, M and Liu, Z (2020). Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin. Transl. Immunol., 9: e1192.
Suartini, GAA; Suprayogi, A; Wibawan, IW; Sendow, I
and Mahardika, G (2014). Intravenous administration of chicken immunoglobulin has a curative effect in experimental infection of canine parvovirus. Glob. Vet., 13: 801-808.
Van Nguyen, S; Umeda, K; Yokoyama, H; Tohya, Y and Kodama, Y (2006). Passive protection of dogs against clinical disease due to canine parvovirus-2 by specific antibody from chicken egg yolk. Can. J. Vet. Res., 70: 62-64.
Winau, F and Winau, R (2002). Emil von Behring and serum therapy. Microbes Infect., 4: 185-188.

Files

Share

How to cite

Statistics